Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis

Press Release

Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 10, 2025, 07:30 ET Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn,…

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment

Press Release

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

Press Release

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ —  Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology

Press Release

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

Press Release

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…